Why are Healius shares crashing 35% on Wednesday?

This healthcare share is crashing deep into the red on Wednesday. What's happening?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healius Ltd (ASX: HLS) shares are back from their trading halt and crashing deep into the red.

In morning trade, the healthcare company's shares are down 35% to $1.19.

As a comparison, the ASX 200 index is trading broadly flat.

A woman looks shocked as she drinks a coffee while reading the paper.

Image source: Getty Images

Why are Healius shares crashing?

Investors have been hitting the sell button today after the company completed the institutional component of a heavily discounted entitlement offer.

According to the release, the company has raised a total of approximately $154 million at $1.20 per new share. This represents a 35% discount to where Healius shares last traded.

The company notes that the institutional entitlement offer was well supported by existing Healius institutional shareholders. Approximately 92% of entitlements available to eligible institutional shareholders were taken up.

Entitlements not taken up by eligible institutional shareholders and entitlements of ineligible institutional shareholders were sold at the $1.20 per share offer price.

The company will now push ahead with a retail entitlement offer aiming to raise a further $33 million.

Why is it raising funds?

Healius will use the proceeds from the entitlement offer to reduce its net debt and reset its balance sheet with appropriate gearing.

This capital raising coincides with the company making an agreement with its lenders to waive its gearing covenant for the first half of 2024 and temporarily increase the covenant from 3.5 times to 4 times at 30 June 2024.

Following the completion of the entitlement offer, Healius expects to have sufficient financial flexibility and liquidity. Though, it is worth noting that part of the agreement will see the company suspend its dividend in FY 2024.

Following today's disappointing decline, Healius shares are now down approximately 64% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »